GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Float Percentage Of Total Shares Outstanding

Accelerate Diagnostics (STU:1A80) Float Percentage Of Total Shares Outstanding : 58.70% (As of Jun. 06, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Accelerate Diagnostics's float shares is 13.86 Mil. Accelerate Diagnostics's total shares outstanding is 23.61 Mil. Accelerate Diagnostics's float percentage of total shares outstanding is 58.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Accelerate Diagnostics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Accelerate Diagnostics's Institutional Ownership is 3.11%.


Accelerate Diagnostics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Accelerate Diagnostics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=13.86/23.61
=58.70%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerate Diagnostics (STU:1A80) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines